Top

Published in:

Open Access 01-12-2019 | Acute Kidney Injury | Review

Mesenchymal stem cell therapy targeting mitochondrial dysfunction in acute kidney injury

Authors: Lingfei Zhao, Chenxia Hu, Ping Zhang, Hua Jiang, Jianghua Chen

Published in: Journal of Translational Medicine | Issue 1/2019

Abstract

Mitochondria take part in a network of cellular processes that regulate cell homeostasis. Defects in mitochondrial function are key pathophysiological changes during acute kidney injury (AKI). Mesenchymal stem cells (MSCs) have shown promising regenerative effects in experimental AKI models, but the specific mechanism is still unclear. Some studies have demonstrated that MSCs are able to target mitochondrial dysfunction during AKI. In this review, we summarize these articles, providing an integral and updated view of MSC therapy targeting mitochondrial dysfunction during AKI, which is aimed at promoting the therapeutic effect of MSCs in AKI patients.

Weisbord SD, Palevsky PM. Design of clinical trials in acute kidney injury: lessons from the past and future directions. Semin Nephrol. 2016;36(1):42–52.CrossRefPubMed

Liangos O, Wald R, O’Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol. 2006;1(1):43–51.CrossRefPubMed

Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756–66.CrossRefPubMed

Thakar CV. Perioperative acute kidney injury. Adv Chronic Kidney Dis. 2013;20(1):67–75.CrossRefPubMed

Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. Nat Rev Nephrol. 2014;10(4):193–207.CrossRefPubMed

Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360(9328):219–23.CrossRefPubMed

Lund M, Melbye M, Diaz LJ, Duno M, Wohlfahrt J, Vissing J. Mitochondrial dysfunction and risk of cancer. Br J Cancer. 2015;112(6):1134–40.CrossRefPubMedPubMedCentral

Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983–97.CrossRefPubMed

Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291–312.CrossRefPubMed

10.

Soltoff SP. ATP and the regulation of renal cell function. Annu Rev Physiol. 1986;48:9–31.CrossRefPubMed

11.

Tran M, Tam D, Bardia A, et al. PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest. 2011;121(10):4003–14.CrossRefPubMedPubMedCentral

12.

Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest. 2009;119(5):1275–85.CrossRefPubMedPubMedCentral

13.

Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641–50.CrossRefPubMed

14.

He A, Jiang Y, Gui C, Sun Y, Li J, Wang JA. The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning. Can J Cardiol. 2009;25(6):353–8.CrossRefPubMedPubMedCentral

15.

Hoogduijn MJ, Popp F, Verbeek R, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol. 2010;10(12):1496–500.CrossRefPubMed

16.

Tsubokawa T, Yagi K, Nakanishi C, et al. Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. Am J Physiol Heart Circ Physiol. 2010;298(5):H1320–9.CrossRefPubMed

17.

Hoch AI, Binder BY, Genetos DC, Leach JK. Differentiation-dependent secretion of proangiogenic factors by mesenchymal stem cells. PLoS ONE. 2012;7(4):e35579.CrossRefPubMedPubMedCentral

18.

Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5):759–65.CrossRefPubMedPubMedCentral

19.

Li X, Michaeloudes C, Zhang Y, et al. Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways. J Allergy Clin Immunol. 2018;141(5):1634–45.CrossRefPubMed

20.

Zhang Y, Yu Z, Jiang D, et al. iPSC-MSCs with high intrinsic MIRO1 and sensitivity to TNF-α yield efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy. Stem Cell Rep. 2016;7(4):749–63.CrossRef

21.

Dimmer KS, Scorrano L. (De)constructing mitochondria: what for. Physiology. 2006;21:233–41.CrossRefPubMed

22.

Hoenig MP, Zeidel ML. Homeostasis, the milieu intérieur, and the wisdom of the nephron. Clin J Am Soc Nephrol. 2014;9(7):1272–81.CrossRefPubMedPubMedCentral

23.

Forbes JM. Mitochondria-power players in kidney function. Trends Endocrinol Metab. 2016;27(7):441–2.CrossRefPubMed

24.

Bagnasco S, Good D, Balaban R, Burg M. Lactate production in isolated segments of the rat nephron. Am J Physiol. 1985;248(4 Pt 2):F522–6.PubMed

25.

Chouchani ET, Pell VR, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515(7527):431–5.CrossRefPubMedPubMedCentral

26.

Zuk A, Bonventre JV. Acute kidney injury. Annu Rev Med. 2016;67:293–307.CrossRefPubMedPubMedCentral

27.

Chouchani ET, Pell VR, James AM, et al. A unifying mechanism for mitochondrial superoxide production during ischemia-reperfusion injury. Cell Metab. 2016;23(2):254–63.CrossRefPubMed

28.

Padanilam BJ. Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. Am J Physiol Renal Physiol. 2003;284(4):F608–27.CrossRefPubMed

29.

Trump BF, Valigorsky JM, Jones RT, Mergner WJ, Garcia JH, Cowley RA. The application of electron microscopy and cellular biochemistry to the autopsy. Observations on cellular changes in human shock. Hum Pathol. 1975;6(4):499–516.CrossRefPubMed

30.

Takasu O, Gaut JP, Watanabe E, et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med. 2013;187(5):509–17.CrossRefPubMedPubMedCentral

31.

Parekh DJ, Weinberg JM, Ercole B, et al. Tolerance of the human kidney to isolated controlled ischemia. J Am Soc Nephrol. 2013;24(3):506–17.CrossRefPubMedPubMedCentral

32.

Bonora M, Wieckowski MR, Chinopoulos C, et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene. 2015;34(12):1475–86.CrossRefPubMed

33.

Funk JA, Schnellmann RG. Persistent disruption of mitochondrial homeostasis after acute kidney injury. Am J Physiol Renal Physiol. 2012;302(7):F853–64.CrossRefPubMed

34.

Ricksten SE, Bragadottir G, Redfors B. Renal oxygenation in clinical acute kidney injury. Crit Care. 2013;17(2):221.CrossRefPubMedPubMedCentral

35.

Zager RA, Johnson AC, Hanson SY. Renal tubular triglyercide accumulation following endotoxic, toxic, and ischemic injury. Kidney Int. 2005;67(1):111–21.CrossRefPubMed

36.

Dröse S, Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv Exp Med Biol. 2012;748:145–69.CrossRefPubMed

37.

Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med. 2000;109(8):665–78.CrossRefPubMed

38.

Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane—from discovery to clinical development. Pharm Res. 2011;28(11):2669–79.CrossRefPubMed

39.

Mukhopadhyay P, Horváth B, Zsengellér Z, et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med. 2012;52(2):497–506.CrossRefPubMed

40.

Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol. 2017;13(10):629–46.CrossRefPubMedPubMedCentral

41.

Virbasius CA, Virbasius JV, Scarpulla RC. NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators. Genes Dev. 1993;7(12A):2431–45.CrossRefPubMed

42.

Virbasius JV, Virbasius CA, Scarpulla RC. Identity of GABP with NRF-2, a multisubunit activator of cytochrome oxidase expression, reveals a cellular role for an ETS domain activator of viral promoters. Genes Dev. 1993;7(3):380–92.CrossRefPubMed

43.

Funk JA, Schnellmann RG. Accelerated recovery of renal mitochondrial and tubule homeostasis with SIRT1/PGC-1α activation following ischemia-reperfusion injury. Toxicol Appl Pharmacol. 2013;273(2):345–54.CrossRefPubMedPubMedCentral

44.

Jesinkey SR, Funk JA, Stallons LJ, et al. Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury. J Am Soc Nephrol. 2014;25(6):1157–62.CrossRefPubMedPubMedCentral

45.

Duann P, Lianos EA, Ma J, Lin PH. Autophagy, innate immunity and tissue repair in acute kidney injury. Int J Mol Sci. 2016;17(5):662.CrossRefPubMedCentral

46.

Zhan M, Brooks C, Liu F, Sun L, Dong Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int. 2013;83(4):568–81.CrossRefPubMedPubMedCentral

47.

Gall JM, Wang Z, Liesa M, et al. Role of mitofusin 2 in the renal stress response. PLoS ONE. 2012;7(1):e31074.CrossRefPubMedPubMedCentral

48.

Xiao X, Hu Y, Quirós PM, Wei Q, López-Otín C, Dong Z. OMA1 mediates OPA1 proteolysis and mitochondrial fragmentation in experimental models of ischemic kidney injury. Am J Physiol Renal Physiol. 2014;306(11):F1318–26.CrossRefPubMedPubMedCentral

49.

Brooks C, Cho SG, Wang CY, Yang T, Dong Z. Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis. Am J Physiol Cell Physiol. 2011;300(3):C447–55.CrossRefPubMed

50.

Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12(1):9–14.CrossRefPubMedPubMedCentral

51.

Jiang M, Liu K, Luo J, Dong Z. Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. Am J Pathol. 2010;176(3):1181–92.CrossRefPubMedPubMedCentral

52.

Livingston MJ, Dong Z. Autophagy in acute kidney injury. Semin Nephrol. 2014;34(1):17–26.CrossRefPubMed

53.

Herzog C, Yang C, Holmes A, Kaushal GP. zVAD-fmk prevents cisplatin-induced cleavage of autophagy proteins but impairs autophagic flux and worsens renal function. Am J Physiol Renal Physiol. 2012;303(8):F1239–50.CrossRefPubMedPubMedCentral

54.

Kimura T, Takabatake Y, Takahashi A, et al. Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J Am Soc Nephrol. 2011;22(5):902–13.CrossRefPubMedPubMedCentral

55.

Jiang M, Wei Q, Dong G, Komatsu M, Su Y, Dong Z. Autophagy in proximal tubules protects against acute kidney injury. Kidney Int. 2012;82(12):1271–83.CrossRefPubMedPubMedCentral

56.

Szeto HH. Pharmacologic approaches to improve mitochondrial function in AKI and CKD. J Am Soc Nephrol. 2017;28(10):2856–65.CrossRefPubMedPubMedCentral

57.

Saad A, Herrmann S, Eirin A, et al. Phase 2a clinical trial of mitochondrial protection (Elamipretide) during stent revascularization in patients with atherosclerotic renal artery stenosis. Circ Cardiovasc Interv. 2017;10(9):e005487.CrossRefPubMedPubMedCentral

58.

Rong Y, Distelhorst CW. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol. 2008;70:73–91.CrossRefPubMed

59.

Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta. 2004;1644(2–3):107–13.CrossRefPubMed

60.

Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175–93.CrossRefPubMedPubMedCentral

61.

Ju GQ, Cheng J, Zhong L, et al. Microvesicles derived from human umbilical cord mesenchymal stem cells facilitate tubular epithelial cell dedifferentiation and growth via hepatocyte growth factor induction. PLoS ONE. 2015;10(3):e0121534.CrossRefPubMedPubMedCentral

62.

Xing L, Cui R, Peng L, et al. Mesenchymal stem cells, not conditioned medium, contribute to kidney repair after ischemia-reperfusion injury. Stem Cell Res Ther. 2014;5(4):101.CrossRefPubMedPubMedCentral

63.

Imberti B, Morigi M, Tomasoni S, et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol. 2007;18(11):2921–8.CrossRefPubMed

64.

Geng X, Hong Q, Wang W, et al. Biological membrane-packed mesenchymal stem cells treat acute kidney disease by ameliorating mitochondrial-related apoptosis. Sci Rep. 2017;7:41136.CrossRefPubMedPubMedCentral

65.

Peng X, Xu H, Zhou Y, et al. Human umbilical cord mesenchymal stem cells attenuate cisplatin-induced acute and chronic renal injury. Exp Biol Med. 2013;238:960–70.CrossRef

66.

Jiao X, Cai J, Yu X, Ding X. Paracrine activation of the Wnt/β-catenin pathway by bone marrow stem cell attenuates cisplatin-induced kidney injury. Cell Physiol Biochem. 2017;44(5):1980–94.CrossRefPubMed

67.

Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet. 2010;6(1):e1000795.CrossRefPubMedPubMedCentral

68.

Gu D, Zou X, Ju G, Zhang G, Bao E, Zhu Y. Mesenchymal stromal cells derived extracellular vesicles ameliorate acute renal ischemia reperfusion injury by inhibition of mitochondrial fission through miR-30. Stem Cells Int. 2016;2016:2093940.CrossRefPubMedPubMedCentral

69.

Lempiäinen J, Finckenberg P, Levijoki J, Mervaala E. AMPK activator AICAR ameliorates ischaemia reperfusion injury in the rat kidney. Br J Pharmacol. 2012;166(6):1905–15.CrossRefPubMedPubMedCentral

70.

Perico L, Morigi M, Rota C, et al. Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nat Commun. 2017;8(1):983.CrossRefPubMedPubMedCentral

71.

Bell EL, Guarente L. The SirT3 divining rod points to oxidative stress. Mol Cell. 2011;42(5):561–8.CrossRefPubMedPubMedCentral

72.

Morigi M, Perico L, Rota C, et al. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J Clin Invest. 2015;125(2):715–26.CrossRefPubMedPubMedCentral

73.

Zhao W, Zhang L, Chen R, et al. SIRT3 protects against acute kidney injury via AMPK/mTOR-regulated autophagy. Front Physiol. 2018;9:1526.CrossRefPubMedPubMedCentral

74.

Paliwal S, Chaudhuri R, Agrawal A, Mohanty S. Regenerative abilities of mesenchymal stem cells through mitochondrial transfer. J Biomed Sci. 2018;25(1):31.CrossRefPubMedPubMedCentral

75.

Ma Z, Yang H, Liu H, et al. Mesenchymal stem cell-cardiomyocyte interactions under defined contact modes on laser-patterned biochips. PLoS ONE. 2013;8(2):e56554.CrossRefPubMedPubMedCentral

76.

Jiang D, Gao F, Zhang Y, et al. Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage. Cell Death Dis. 2016;7(11):e2467.CrossRefPubMedPubMedCentral

77.

Jackson MV, Morrison TJ, Doherty DF, et al. Mitochondrial transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells. 2016;34(8):2210–23.CrossRefPubMedPubMedCentral

78.

Plotnikov EY, Khryapenkova TG, Galkina SI, Sukhikh GT, Zorov DB. Cytoplasm and organelle transfer between mesenchymal multipotent stromal cells and renal tubular cells in co-culture. Exp Cell Res. 2010;316(15):2447–55.CrossRefPubMed

79.

Wang Y, He J, Pei X, Zhao W. Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models. Nephrology. 2013;18(3):201–8.CrossRefPubMed

80.

Zhang G, Wang D, Miao S, Zou X, Liu G, Zhu Y. Extracellular vesicles derived from mesenchymal stromal cells may possess increased therapeutic potential for acute kidney injury compared with conditioned medium in rodent models: a meta-analysis. Exp Ther Med. 2016;11(4):1519–25.CrossRefPubMedPubMedCentral

81.

Hossain MA, Chowdhury T, Bagul A. Imaging modalities for the in vivo surveillance of mesenchymal stromal cells. J Tissue Eng Regen Med. 2015;9(11):1217–24.CrossRefPubMed

82.

Du T, Cheng J, Zhong L, et al. The alleviation of acute and chronic kidney injury by human Wharton’s jelly-derived mesenchymal stromal cells triggered by ischemia-reperfusion injury via an endocrine mechanism. Cytotherapy. 2012;14(10):1215–27.CrossRefPubMed

83.

Burst VR, Gillis M, Pütsch F, et al. Poor cell survival limits the beneficial impact of mesenchymal stem cell transplantation on acute kidney injury. Nephron Exp Nephrol. 2010;114(3):e107–16.CrossRefPubMed

84.

Semedo P, Correa-Costa M, Antonio CM, et al. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells. 2009;27(12):3063–73.PubMed

85.

Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol. 2012;3:359.CrossRefPubMedPubMedCentral

Title: Mesenchymal stem cell therapy targeting mitochondrial dysfunction in acute kidney injury
Authors: Lingfei Zhao
Chenxia Hu
Ping Zhang
Hua Jiang
Jianghua Chen
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Acute Kidney Injury
Acute Kidney Injury
Published in: Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-019-1893-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Mesenchymal stem cell therapy targeting mitochondrial dysfunction in acute kidney injury

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients

TREM2 regulates obesity-induced insulin resistance via adipose tissue remodeling in mice of high-fat feeding

Bone marrow donor selection and characterization of MSCs is critical for pre-clinical and clinical cell dose production

Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization

Herpes simplex virus-1 (HSV-1) infection induces a potent but ineffective IFN-λ production in immune cells of AD and PD patients

Bringing radiomics into a multi-omics framework for a comprehensive genotype–phenotype characterization of oncological diseases

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page